Aragen, a leading Contract Research Development and Manufacturing Organization (CRDMO) for small molecules and biologics, has announced that it is setting up a new biologics manufacturing facility in Bengaluru, India. 

The state-of-the-art facility is part of a $30 million investment, spanning nearly 160,000 sqm, and includes process development labs and multiple GMP manufacturing suites with supporting functions like quality control labs (analytical and microbiology).

The manufacturing suites will be equipped for intensified processing using single-use bioreactors and advanced downstream purification capability to serve it's rapidly expanding biologics customer base.  

The facility will offer integrated solutions from process development, process validation, analytical development, pilot production, large-scale DS manufacturing and stability services. It will have the capability to develop and manufacture mAbs, therapeutic proteins and fusion proteins to augment the company’s bioproduction capability in California, US.

The process development laboratory is scheduled to be operational by the third quarter of FY 24 while the first manufacturing suite will open in the third quarter of FY 25. The facility is designed to include plasmid DNA, mRNA, cell and gene therapy, microbial manufacturing and additional GMP manufacturing suites in the future as demand ramps up.

Aragen, through its subsidiary, Aragen Bioscience Inc., offers a range of in vitro and in vivo services for the discovery, cell line development, production, characterisation and efficacy assessment and development of biologics for human and animal health. Its state-of-the-art R&D facilities are in the San Francisco Bay area.